The stock of Allogene Therapeutics Inc (NASDAQ: ALLO) has increased by 0.29 when compared to last closing price of 3.50. Despite this, the company has experienced a -13.76% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-09 that SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
The 36-month beta value for ALLO is at 0.85. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALLO is 104.72M, and currently, shorts hold a 29.24% of that float. The average trading volume for ALLO on April 17, 2024 was 2.37M shares.
ALLO’s Market Performance
ALLO’s stock has seen a -13.76% decrease for the week, with a -16.33% drop in the past month and a 11.43% gain in the past quarter. The volatility ratio for the week is 7.38%, and the volatility levels for the past 30 days are at 6.50% for Allogene Therapeutics Inc The simple moving average for the last 20 days is -14.85% for ALLO stock, with a simple moving average of -7.85% for the last 200 days.
Analysts’ Opinion of ALLO
Citigroup gave a rating of “Buy” to ALLO, setting the target price at $7 in the report published on December 08th of the previous year.
ALLO Trading at -22.37% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.06% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 7.38%, as shares sank -19.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.10% lower at present.
During the last 5 trading sessions, ALLO fell by -13.64%, which changed the moving average for the period of 200-days by -29.28% in comparison to the 20-day moving average, which settled at $4.08. In addition, Allogene Therapeutics Inc saw 9.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Parker Geoffrey M., who purchase 190 shares at the price of $3.60 back on Jan 30 ’24. After this action, Parker Geoffrey M. now owns 819,590 shares of Allogene Therapeutics Inc, valued at $683 using the latest closing price.
MESSEMER DEBORAH M., the Director of Allogene Therapeutics Inc, sale 18,640 shares at $2.70 during a trade that took place back on Dec 18 ’23, which means that MESSEMER DEBORAH M. is holding 62,456 shares at $50,317 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -1965.17 for the present operating margin
- -68.24 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -2021.38. The total capital return value is set at -0.52.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.5. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 859.09.
Currently, EBITDA for the company is -287.05 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 3778.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.58.
Conclusion
In conclusion, Allogene Therapeutics Inc (ALLO) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
